Global Nonalcoholic Steatohepatitis Drugs Pipeline Market Growth, Share, Size, Trends and Forecast (2024 - 2030)
Segmented by Drug Class;
Drugs Targeting Metabolic Homeostasis, Drugs Acting on Insulin Resistance, Drugs to Prevent and Treat Inflammation and Drugs Preventing Oxidative Stress or Fibrosis.Segmented by Mechanism;
Farnesoid X receptor Modulation, Peroxisome proliferator-activated receptor agonist, C chemokine receptor Antagonist, Apoptosis signal-regulated kinase-1 inhibitor, Oral acetyl-CoA carboxylase (ACC) inhibitor, Fibroblast growth factor 21 (FGF 21) inhibitor and Others.Segmented by Development Phase;
Discovery, Preclinical, Phase 1 CT, Phase 2 CT, Phase 3 CT and IND/CTA Filed.Segmented by Geography;
North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2020 - 2030).Introduction
Global Nonalcoholic Steatohepatitis Drugs Pipeline Market (USD Million), 2020 - 2030
# | Global |
---|---|
2020 | 69.6 |
2021 | 78.5 |
2022 | 82.9 |
2023 | 96.3 |
2024 | 104.6 |
2025 | 116.1 |
2026 | 136.7 |
2027 | 152.7 |
2028 | 177.3 |
2029 | 197.0 |
2030 | 201.1 |
In the year 2023, the Global Nonalcoholic Steatohepatitis Drugs Pipeline Market was valued at USD 272.23 million. The size of this market is expected to increase to USD 274.53 million by the year 2030, while growing at a Compounded Annual Growth Rate (CAGR) of 32.8%.
Global Nonalcoholic Steatohepatitis Drugs Pipeline Market Report Snapshot
Parameters | Description |
---|---|
Market | Global Nonalcoholic Steatohepatitis Drugs Pipeline Market |
Study Period | 2020 - 2030 |
Base Year (for Nonalcoholic Steatohepatitis Drugs Pipeline Market Size Estimates) | 2023 |
Study Scope |
|
Market Segmentation |
|
Geographical Coverage |
|
Company Coverage |
|
Premium Insights |
|
Market Analysis
This report extensively covers different segments of Global Nonalcoholic Steatohepatitis Drugs Pipeline Market and provides an in depth analysis (including revenue analysis for both historic and forecast periods) for all the market segments. In this report, the analysis for every market segment is substantiated with relevant data points and, insights that are generated from analysis of these data points (data trends and patterns).
Global Nonalcoholic Steatohepatitis Drugs Pipeline Market Analysis
In this report, the Global Nonalcoholic Steatohepatitis Drugs Pipeline Market has been segmented by Drug Class, Mechanism, Development Phase and Geography.
Global Nonalcoholic Steatohepatitis Drugs Pipeline Market, Segmentation by Drug Class
The Global Nonalcoholic Steatohepatitis Drugs Pipeline Market has been segmented by Drug Class into Drugs Targeting Metabolic Homeostasis, Drugs Acting on Insulin Resistance, Drugs to Prevent and Treat Inflammation and Drugs Preventing Oxidative Stress or Fibrosis. The complete Global Nonalcoholic Steatohepatitis Drugs Pipeline Market segmentation by Drug Class can be seen below:
- Global Nonalcoholic Steatohepatitis Drugs Pipeline Market, By Drug Class
- Drugs Targeting Metabolic Homeostasis
- Drugs Acting on Insulin Resistance
- Drugs to Prevent and Treat Inflammation
- Drugs Preventing Oxidative Stress or Fibrosis
This report provides market size in USD Million and Year on Year (YOY) growth analysis for all the Drug Classs mentioned above for historic (2020 - 2023) and forecast (2024 - 2030) periods with 2023 considered as the base year.
The report also provides an analysis of why the market size of the various segments by Drug Class is increasing or decreasing with time along with the reasons for changes in the YOY growth with time.
Global Nonalcoholic Steatohepatitis Drugs Pipeline Market, by Drug Class (USD Million), 2020 - 2030
# | Drugs Targeting Metabolic Homeostasis | Drugs Acting on Insulin Resistance | Drugs to Prevent and Treat Inflammation | Drugs Preventing Oxidative Stress or Fibrosis |
---|---|---|---|---|
2020 | 67.5 | 86.7 | 63.2 | 109.3 |
2021 | 78.0 | 88.0 | 69.6 | 110.0 |
2022 | 87.9 | 104.1 | 75.8 | 126.0 |
2023 | 98.0 | 110.4 | 88.8 | 137.6 |
2024 | 114.8 | 121.1 | 94.5 | 152.3 |
2025 | 126.2 | 144.4 | 102.6 | 165.3 |
2026 | 141.4 | 160.6 | 117.2 | 174.9 |
2027 | 151.9 | 177.6 | 128.0 | 197.8 |
2028 | 165.6 | 182.1 | 135.4 | 199.9 |
2029 | 185.7 | 184.1 | 136.1 | 223.5 |
2030 | 212.6 | 217.1 | 143.8 | 246.4 |
Global Nonalcoholic Steatohepatitis Drugs Pipeline Market, Segmentation by Mechanism
The Global Nonalcoholic Steatohepatitis Drugs Pipeline Market has been segmented by Mechanism into Farnesoid X receptor Modulation, Peroxisome proliferator-activated receptor agonist, C chemokine receptor Antagonist, Apoptosis signal-regulated kinase-1 inhibitor, Oral acetyl-CoA carboxylase (ACC) inhibitor, Fibroblast growth factor 21 (FGF 21) inhibitor and Others. The complete Global Nonalcoholic Steatohepatitis Drugs Pipeline Market segmentation by Mechanism can be seen below:
- Global Nonalcoholic Steatohepatitis Drugs Pipeline Market, By Mechanism
- Farnesoid X receptor Modulation
- Peroxisome proliferator-activated receptor agonist
- C chemokine receptor Antagonist
- Apoptosis signal-regulated kinase-1 inhibitor
- Oral acetyl-CoA carboxylase (ACC) inhibitor
- Fibroblast growth factor 21 (FGF 21) inhibitor
- Others
This report provides market size in USD Million and Year on Year (YOY) growth analysis for all the Mechanisms mentioned above for historic (2020 - 2023) and forecast (2024 - 2030) periods with 2023 considered as the base year.
The report also provides an analysis of why the market size of the various segments by Mechanism is increasing or decreasing with time along with the reasons for changes in the YOY growth with time.
Global Nonalcoholic Steatohepatitis Drugs Pipeline Market, by Mechanism (USD Million), 2020 - 2030
# | Farnesoid X receptor Modulation | Peroxisome proliferator-activated receptor agonist | C chemokine receptor Antagonist | Apoptosis signal-regulated kinase-1 inhibitor | Oral acetyl-CoA carboxylase (ACC) inhibitor | Fibroblast growth factor 21 (FGF 21) inhibitor | Others |
---|---|---|---|---|---|---|---|
2020 | 112.2 | 104.5 | 87.3 | 96.5 | 86.1 | 72.8 | 73.1 |
2021 | 120.0 | 108.8 | 103.3 | 97.5 | 98.5 | 76.7 | 78.3 |
2022 | 141.2 | 113.4 | 117.3 | 107.8 | 113.5 | 87.7 | 88.2 |
2023 | 158.4 | 124.3 | 124.2 | 115.4 | 130.7 | 88.4 | 104.0 |
2024 | 184.8 | 145.3 | 142.5 | 133.1 | 143.2 | 92.3 | 120.5 |
2025 | 211.6 | 166.5 | 167.4 | 159.5 | 147.7 | 108.4 | 125.9 |
2026 | 250.4 | 182.2 | 168.3 | 164.2 | 150.6 | 113.0 | 128.1 |
2027 | 295.7 | 200.0 | 168.5 | 174.7 | 175.7 | 119.1 | 133.5 |
2028 | 323.9 | 216.1 | 177.7 | 182.7 | 200.2 | 121.4 | 145.6 |
2029 | 372.5 | 241.4 | 184.7 | 195.5 | 236.0 | 143.1 | 156.0 |
2030 | 374.2 | 252.5 | 188.8 | 207.3 | 240.9 | 160.2 | 182.7 |
Global Nonalcoholic Steatohepatitis Drugs Pipeline Market, Segmentation by Development Phase
The Global Nonalcoholic Steatohepatitis Drugs Pipeline Market has been segmented by Development Phase into Discovery, Preclinical, Phase 1 CT, Phase 2 CT, Phase 3 CT and IND/CTA Filed. The complete Global Nonalcoholic Steatohepatitis Drugs Pipeline Market segmentation by Development Phase can be seen below:
- Global Nonalcoholic Steatohepatitis Drugs Pipeline Market, By Development Phase
- Discovery
- Preclinical
- Phase 1 CT
- Phase 2 CT
- Phase 3 CT
- IND/CTA Filed
This report provides market size in USD Million and Year on Year (YOY) growth analysis for all the Development Phases mentioned above for historic (2020 - 2023) and forecast (2024 - 2030) periods with 2023 considered as the base year.
The report also provides an analysis of why the market size of the various segments by Development Phase is increasing or decreasing with time along with the reasons for changes in the YOY growth with time.
Global Nonalcoholic Steatohepatitis Drugs Pipeline Market, by Development Phase (USD Million), 2020 - 2030
# | Discovery | Preclinical | Phase 1 CT | Phase 2 CT | Phase 3 CT | IND/CTA Filed |
---|---|---|---|---|---|---|
2020 | 62.9 | 83.1 | 99.3 | 82.7 | 81.4 | 88.1 |
2021 | 72.1 | 90.1 | 106.0 | 94.7 | 86.1 | 104.0 |
2022 | 86.0 | 94.0 | 117.5 | 106.6 | 87.0 | 117.7 |
2023 | 87.2 | 100.7 | 127.2 | 110.9 | 97.4 | 127.0 |
2024 | 98.3 | 115.9 | 132.7 | 121.2 | 108.9 | 128.7 |
2025 | 106.6 | 125.6 | 145.7 | 129.6 | 128.3 | 131.2 |
2026 | 119.5 | 148.0 | 162.0 | 131.9 | 129.8 | 142.1 |
2027 | 142.2 | 158.2 | 162.5 | 154.1 | 151.9 | 170.4 |
2028 | 150.2 | 169.2 | 182.4 | 155.0 | 173.0 | 172.0 |
2029 | 152.2 | 189.6 | 216.0 | 181.5 | 200.2 | 177.7 |
2030 | 175.7 | 202.9 | 258.5 | 213.4 | 231.9 | 183.4 |
Global Nonalcoholic Steatohepatitis Drugs Pipeline Market, Segmentation by Geography
In this report, the Global Nonalcoholic Steatohepatitis Drugs Pipeline Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Global Nonalcoholic Steatohepatitis Drugs Pipeline Market Share (%), by Geographical Region, 2023
North America | Europe | Asia Pacific | Middle East & Africa | Latin America |
---|---|---|---|---|
20 | 10 | 15 | 5 | 50 |
Find below the list of Countries covered in each of the aforementioned geographical regions:
North America - United States, Canada and Mexico
Latin America - Brazil, Argentina and Rest of Latin America
Europe - Germany, United Kingdom, France, Italy, Spain and Rest of Europe
Asia Pacific - Japan, China, India, Australia & New Zealand, South Korea, ASEAN (Association of South East Asian Nations) and Rest of Asia Pacific
Middle East & Africa - GCC Countries, Egypt, Israel, South Africa, Rest of Middle East & Africa
This report provides market size in USD Million and Year on Year (YOY) percentage growth analysis for the Nonalcoholic Steatohepatitis Drugs Pipeline Market in all the Regions and Countries (specified above) for historic (2020 - 2023) and forecast (2024 - 2030) Periods with 2023 considered as the base year.
This report also provides an analysis of why the market size of Nonalcoholic Steatohepatitis Drugs Pipeline in various regions and countries is increasing or decreasing with time along with the reasons for changes in the YOY growth with time.
Market Dynamics
This report provides an in depth analysis of various factors that impact the dynamics of Global Nonalcoholic Steatohepatitis Drugs Pipeline Market. These factors include; Market Drivers, Restraints and Opportunities Analysis, Market Opportunity Mapping, PEST (Political, Economic, Social and Technological) Analysis and Porter's Five Forces Analysis.
Drivers, Restraints and Opportunity Analysis
- The factors driving the growth of Global Nonalcoholic Steatohepatitis Drugs Pipeline Market will be discussed in detail in the full report.
- The factors hindering the growth of Global Nonalcoholic Steatohepatitis Drugs Pipeline Market will be discussed in detail in the full report.
- The new opportunities in Global Nonalcoholic Steatohepatitis Drugs Pipeline Market will be discussed in detail in the full report.
- Global Nonalcoholic Steatohepatitis Drugs Pipeline Market Drivers will be discussed in detail in the full report.
- Global Nonalcoholic Steatohepatitis Drugs Pipeline Market Restraints will be discussed in detail in the full report.
- Global Nonalcoholic Steatohepatitis Drugs Pipeline Market Opportunities will be discussed in detail in the full report.
Market Opportunity Map
This report provides market opportunity map for Nonalcoholic Steatohepatitis Drugs Pipeline Market. The opportunity map (by market segments; Drug Class, Mechanism and Development Phase) is calculated based on current year market estimates, CAGR and collective revenue over the forecast period. Since, CAGR has been estimated considering all the factors impacting the market; starting from the company's presence, buyer behaviour, to government interference or support. The opportunity map inherently considers all the aforementioned factors impacting the market. The bubble size reflects the estimated opportunity for a particular segment or region, therefore, bigger the bubble size, larger the opportunity.
Global Nonalcoholic Steatohepatitis Drugs Pipeline Market, Opportunity Map, By Region (2020 - 2030)
North America | Europe | Asia Pacific | Middle East & Africa | Latin America |
---|---|---|---|---|
20 | 10 | 15 | 5 | 50 |
PEST (Political, Economic, Social and Technological) Analysis
This report provides PEST analysis of Nonalcoholic Steatohepatitis Drugs Pipeline Market. Various factors such as government interference in the market such as regulations (which include but are not limited to pricing and intellectual property policies) that might impact the market are analysed.
This report also provides an analysis of Economic factors affecting the market such as; purchasing power, which directly influences the market growth.
This report also provides an analysis of social factors such as social norms or cultural beliefs inhibiting or promoting the growth of the market
As part of PEST analysis, this report also provides analysis of the impact of Technological factors on growth or decline of a market.
- In depth analysis and insights about the impact of political factors on this market will be provided in the final report.
- In depth analysis and insights about the impact of economic factors on this market will be provided in the final report.
- In depth analysis and insights about the impact of social factors on this market will be provided in the final report.
- In depth analysis and insights about the impact of technological factors on this market will be provided in the final report.
Porter's Five Force Analysis
This report provides Porter's Five Forces analysis of Global Nonalcoholic Steatohepatitis Drugs Pipeline Market, which include; Bargaining Power of Suppliers, Bargaining Power of Buyers, Threat of New Entrants, Threat of Substitutes and Competitive Rivalry.
Bargaining Power of Suppliers:
Various factors such as; Supplier Switching Costs Relative to Firm Switching Costs, Supplier Competition and Possibility of Forward Integration, Presence of Substitute Inputs, Strength of Distribution Channels, and Supplier Concentration to Firm Concentration Ratio would be analysed to estimate bargaining power of suppliers in the Global Nonalcoholic Steatohepatitis Drugs Pipeline Market. Bargaining power of suppliers will be reported on a scale of 0-10 with 0 being the lowest value and 10 being the highest value.
Bargaining Power of Suppliers
Supplier Switching Costs Relative To Firm Switching Costs | Strength of Distribution Channels | Supplier Concentration to firm Concentration Ratio | Presence of Substitute Inputs | Supplier Competition and Possibly of Forward Integration |
---|---|---|---|---|
20 | 10 | 15 | 5 | 50 |
Bargaining Power of Buyers:
Various factors such as; Buyer Concentration to Firm Concentration Ratio, Buyer Switching Costs, Availability of Existing Substitute Products, Buyer Price Sensitivity, and Degree of Dependency upon Existing Channels of Distribution would be analysed to estimate bargaining power of buyers in the Global Nonalcoholic Steatohepatitis Drugs Pipeline Market. Bargaining power of buyers will be reported on a scale of 0-10 with 0 being the lowest value and 10 being the highest value.
Bargaining Power of Buyers
Buyer Competition to Firm Concentration Ratio | Buyer Switching Costs | Availability of existing Substitute Products | Buyer Price Sensitivity | Degree of Dependency upon Existing Channels of Distribution |
---|---|---|---|---|
10 | 15 | 25 | 45 | 32 |
Threat of Substitutes:
Various factors such as; Availability of Substitutes, Number of Available Substitutes, Price of Substitute Products, Buyer Switching Costs, and Buyer Propensity to Substitute would be analysed to estimate threat of substitutes in the Global Nonalcoholic Steatohepatitis Drugs Pipeline Market. Threat of substitutes will be reported on a scale of 0-10 with 0 being the lowest value and 10 being the highest value.
Threat of Substitutes:
Availability of Substitutes | Number of Available Substitutes | Price of Substitute Products | Buyer Switching Costs | Buyer Propensity to Substitute |
---|---|---|---|---|
20 | 35 | 10 | 2 | 5 |
Threat of New Entrants:
Various factors such as; Barriers to Entry, Economies of Scale, Product Differentiation, Customer Loyalty, Network Effect, and Access to Distribution Channels would be analysed to estimate threat of new entrants in the Global Nonalcoholic Steatohepatitis Drugs Pipeline Market. Threat of new entrants will be reported on a scale of 0-10 with 0 being the lowest value and 10 being the highest value.
Threat of New Entrants:
Barriers to entry | Economics of scale | Product Differentiation | Customer Loyalty | Network Effect | Access to Ditribution Channels |
---|---|---|---|---|---|
2 | 35 | 25 | 10 | 15 | 55 |
Competitive Rivalry:
Various factors such as; Firm concentration Ratio, Level of Advertising Expense, Sustainable Competitive Advantage through Innovation, Competitive Strategy and Degree of Transparency would be analysed to estimate competitive rivalry in the Global Nonalcoholic Steatohepatitis Drugs Pipeline Market. Competitive rivalry will be reported on a scale of 0-10 with 0 being the lowest value and 10 being the highest value.
Industry Rivalry:
Firm Concentration Ratio | Level of Advertising Expense | Sustainable Competitive Adavantage through Innovation | Degree of Transparency | Competitive strategy |
---|---|---|---|---|
5 | 10 | 15 | 35 | 45 |
Competitive Landscape Analysis
Key players in Global Nonalcoholic Steatohepatitis Drugs Pipeline Market include, Tobira Therapeutics, Inc., Genfit SA, Intercept Pharmaceuticals Inc.,, Gilead Sciences, Inc, Bristol-Mayers Squibb and Comnay, Merck KGaA, NGM Biopharmaceuticals and Galectin Therapeutics Inc.
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
Company SWOT Analysis
This report also provides Heat map analysis of Products/Services Offered by different companies operating in this market.
Competitors Products/Services Heat Map Analysis
Company Vs. Product/Service | Company 1 | Company 2 | Company 3 | Company 4 | Company 5 | Company 6 | Company 7 | Company 8 | Company 9 | Company 10 |
---|---|---|---|---|---|---|---|---|---|---|
Product 1/Service 1 | ||||||||||
Product 2/Service 2 | ||||||||||
Product 3/Service 3 | ||||||||||
Product 4/Service 4 | ||||||||||
Product 5/Service 5 | ||||||||||
Product 6/Service 6 | ||||||||||
Product 7/Service 7 | ||||||||||
Product 8/Service 8 |
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Mechanism
- Market Snapshot, By Development Phase
- Market Snapshot, By Region
- Market Opportunity Map
- Global Nonalcoholic Steatohepatitis Drugs Pipeline Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Restraints
- Opportunities
- Regulatory Scenario
- Reimbursement Scenario
- Mergers & Acquisitions, Collaborations & Partnerships, Agreements
- Pipeline Analysis/Technological Advancements
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bragaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Industry Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Global Nonalcoholic Steatohepatitis Drugs Pipeline Market, By Drug Class, 2022 - 2032 (USD Million)
- Introduction
- Market Share Analysis, 2024 and 2030 (%)
- Y-o-Y Growth Analysis, 2021 - 2030
- Segment Trends
- Drugs Targeting Metabolic Homeostasis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2030 (USD Million)
- Drugs Acting on Insulin Resistance
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2030 (USD Million)
- Drugs to Prevent and Treat Inflammation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2030 (USD Million)
- Drugs Preventing Oxidative Stress or Fibrosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2030 (USD Million)
- Drugs Targeting Metabolic Homeostasis
- Global Nonalcoholic Steatohepatitis Drugs Pipeline Market, By Mechanism, 2022 - 2032 (USD Million)
- Introduction
- Market Share Analysis, 2024 and 2030 (%)
- Y-o-Y Growth Analysis, 2021 - 2030
- Segment Trends
- Farnesoid X receptor Modulation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2030 (USD Million)
- Peroxisome proliferator-activated receptor agonist
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2030 (USD Million)
- C chemokine receptor Antagonist
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2030 (USD Million)
- Apoptosis signal-regulated kinase-1 inhibitor
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2030 (USD Million)
- Oral acetyl-CoA carboxylase (ACC) inhibitor
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2030 (USD Million)
- Fibroblast growth factor 21 (FGF 21) inhibitor
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2030 (USD Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2030 (USD Million)
- Farnesoid X receptor Modulation
- Global Nonalcoholic Steatohepatitis Drugs Pipeline Market, By Development Phase, 2022 - 2032 (USD Million)
- Introduction
- Market Share Analysis, 2024 and 2030 (%)
- Y-o-Y Growth Analysis, 2021 - 2030
- Segment Trends
- Discovery
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2030 (USD Million)
- Preclinical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2030 (USD Million)
- Phase 1 CT
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2030 (USD Million)
- Phase 2 CT
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2030 (USD Million)
- Phase 3 CT
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2030 (USD Million)
- IND/CTA Filed
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2030 (USD Million)
- Discovery
- Global Nonalcoholic Steatohepatitis Drugs Pipeline Market, By Geography, 2022 - 2032 (USD Million)
- Introduction
- Market Share Analysis, 2024 and 2030 (%)
- Y-o-Y Growth Analysis, 2021 - 2030
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2030 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Mechanism, 2020 - 2030 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Development Phase, 2020 - 2030 (USD Million)
- United States
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2030 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Mechanism, 2020 - 2030 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Development Phase, 2020 - 2030 (USD Million)
- Canada
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2030 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Mechanism, 2020 - 2030 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Development Phase, 2020 - 2030 (USD Million)
- United States
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2030 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Mechanism, 2020 - 2030 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Development Phase, 2020 - 2030 (USD Million)
- Germany
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2030 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Mechanism, 2020 - 2030 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Development Phase, 2020 - 2030 (USD Million)
- United Kingdom
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2030 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Mechanism, 2020 - 2030 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Development Phase, 2020 - 2030 (USD Million)
- France
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2030 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Mechanism, 2020 - 2030 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Development Phase, 2020 - 2030 (USD Million)
- Italy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2030 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Mechanism, 2020 - 2030 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Development Phase, 2020 - 2030 (USD Million)
- Spain
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2030 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Mechanism, 2020 - 2030 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Development Phase, 2020 - 2030 (USD Million)
- Rest of Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2030 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Mechanism, 2020 - 2030 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Development Phase, 2020 - 2030 (USD Million)
- Germany
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2030 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Mechanism, 2020 - 2030 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Development Phase, 2020 - 2030 (USD Million)
- Japan
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2030 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Mechanism, 2020 - 2030 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Development Phase, 2020 - 2030 (USD Million)
- China
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2030 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Mechanism, 2020 - 2030 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Development Phase, 2020 - 2030 (USD Million)
- India
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2030 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Mechanism, 2020 - 2030 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Development Phase, 2020 - 2030 (USD Million)
- Australia & New Zealand
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2030 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Mechanism, 2020 - 2030 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Development Phase, 2020 - 2030 (USD Million)
- South Korea
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2030 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Mechanism, 2020 - 2030 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Development Phase, 2020 - 2030 (USD Million)
- ASEAN (Association of South East Asian Countries)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2030 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Mechanism, 2020 - 2030 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Development Phase, 2020 - 2030 (USD Million)
- Rest of Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2030 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Mechanism, 2020 - 2030 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Development Phase, 2020 - 2030 (USD Million)
- Japan
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2030 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Mechanism, 2020 - 2030 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Development Phase, 2020 - 2030 (USD Million)
- Brazil
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2030 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Mechanism, 2020 - 2030 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Development Phase, 2020 - 2030 (USD Million)
- Mexico
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2030 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Mechanism, 2020 - 2030 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Development Phase, 2020 - 2030 (USD Million)
- Argentina
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2030 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Mechanism, 2020 - 2030 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Development Phase, 2020 - 2030 (USD Million)
- Rest of Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2030 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Mechanism, 2020 - 2030 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Development Phase, 2020 - 2030 (USD Million)
- Brazil
- Middle East & Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2030 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Mechanism, 2020 - 2030 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Development Phase, 2020 - 2030 (USD Million)
- GCC
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2030 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Mechanism, 2020 - 2030 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Development Phase, 2020 - 2030 (USD Million)
- Israel
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2030 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Mechanism, 2020 - 2030 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Development Phase, 2020 - 2030 (USD Million)
- South Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2030 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Mechanism, 2020 - 2030 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Development Phase, 2020 - 2030 (USD Million)
- Rest of Middle East & Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2030 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Mechanism, 2020 - 2030 (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Development Phase, 2020 - 2030 (USD Million)
- GCC
- North America
- Global Nonalcoholic Steatohepatitis Drugs Pipeline Market, By Drug Class, 2022 - 2032 (USD Million)
- Competitive Landscape
- Heat Map Analysis
- Company Profiles
- Tobira Therapeutics, Inc.
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Genfit SA
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Intercept Pharmaceuticals Inc.,
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Gilead Sciences, Inc
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Bristol-Mayers Squibb and Comnay
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Merck KGaA
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- NGM Biopharmaceuticals
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Galectin Therapeutics Inc.
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Tobira Therapeutics, Inc.
- Analyst Views
- Future Outlook of the Market
ReAnIn's Most Viewed Titles:
In the year 2023, the Global Non-invasive Aesthetic Treatment Market was valued at USD xx.x million. The size of this market is expected to increase to USD xx.x million by the year 2030, while growing at a Compounded Annual Growth Rate (CAGR) of x.x%
In the year 2023, the Global Non-Destructive Medical Technologies Market was valued at USD xx.x million. The size of this market is expected to increase to USD xx.x million by the year 2030, while growing at a Compounded Annual Growth Rate (CAGR) of x.x%
In the year 2023, the Global Non-Hospital-Based Point-Of-Care Diagnostic Products Market was valued at USD xx.x million. The size of this market is expected to increase to USD xx.x million by the year 2030, while growing at a Compounded Annual Growth Rate (CAGR) of x.x%
In the year 2023, the Global Non-Hyaluronic Acid Dermal Filler Market was valued at USD xx.x million. The size of this market is expected to increase to USD xx.x million by the year 2030, while growing at a Compounded Annual Growth Rate (CAGR) of x.x%